Accès gratuit
Numéro
Med Sci (Paris)
Volume 18, Numéro 6-7, Juin–Juillet 2002
Page(s) 709 - 716
Section M/S Revues : Articles de Synthèse
DOI https://doi.org/10.1051/medsci/20021867709
Publié en ligne 15 juin 2002
  1. Hunter R, Dayan AD, Wilson J. Alzheimer’s disease in one monozygotic twin.J Neurol Neurosurg Psychiatry 1972; 35 : 707–10. [Google Scholar]
  2. Hardy J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 1997; 20 : 154–9. [Google Scholar]
  3. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: highavidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90 : 1977–81. [Google Scholar]
  4. Chartier-Harlin MC, Parfitt M, Legrain S, et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994; 3 : 569–74. [Google Scholar]
  5. Bickeboller H, Campion D, Brice A, et al. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet 1997; 60 : 439–46. [Google Scholar]
  6. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease metaanalysis consortium. JAMA 1997; 278 : 1349–56. [Google Scholar]
  7. Rao VS, Cupples A, van Duijn CM, et al. Evidence for major gene inheritance of Alzheimer disease in families of patients with and without apolipoprotein E epsilon 4. Am J Hum Genet 1996; 59 : 664–75. [Google Scholar]
  8. Hardy J. Apolipoprotein E in the genetics and epidemiology of Alzheimer’s disease.Am J Med Genet 1995; 60 : 456–60. [Google Scholar]
  9. Rebeck GW, Perls TT, West HL, Sodhi P, Lipsitz LA, Hyman BT. Reduced apolipoprotein epsilon 4 allele frequency in the oldest old Alzheimer’s patients and cognitively normal individuals. Neurology 1994; 44 : 1513–6. [Google Scholar]
  10. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997; 17 : 263–4. [Google Scholar]
  11. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoformdependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 2000; 97 : 2892–7. [Google Scholar]
  12. Uchihara T, Duyckaerts C, He Y, et al. ApoE immunoreactivity and microglial cells in Alzheimer’s disease brain. Neurosci Lett 1995; 195 : 5–8. [Google Scholar]
  13. Aleshkov S, Abraham CR, Zannis VI. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer’s disease. Biochemistry 1997; 36 : 10571–80. [Google Scholar]
  14. Russo C, Angelini G, Dapino D, et al. Opposite roles of apolipoprotein E in normal brains and in Alzheimer’s disease. Proc Natl Acad Sci USA 1998; 95 : 15598–602. [Google Scholar]
  15. Lambert JC, Perez-Tur J, Dupire MJ, et al. Distortion of allelic expression of apolipoprotein E in Alzheimer’s disease. Hum Mol Genet 1997; 6 : 2151–4. [Google Scholar]
  16. Bullido MJ, Artiga MJ, Recuero M, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer’s dementia. Nat Genet 1998; 18 : 69–71. [Google Scholar]
  17. Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer’s disease. Hum Mol Genet 1998; 7 : 533–40. [Google Scholar]
  18. Lambert JC, Araria-Goumidi L, Myllykangas L, et al. Contribution of APOE prmoter polymorphisms to Alzheimer’s disease risk. Neurology 2002 (sous presse). [Google Scholar]
  19. Artiga MJ, Bullido MJ, Sastre I, et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 1998; 421 : 105–8. [Google Scholar]
  20. Lambert JC, Berr C, Pasquier F, et al. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer’s disease. Hum Mol Genet 1998; 7 : 1511–6. [Google Scholar]
  21. Lambert JC, Brousseau T, Defosse V, et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study. Hum Mol Genet 2000; 9 : 57–61. [Google Scholar]
  22. Lambert JC, Mann D, Goumidi L, et al. Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer’s disease. Lancet 2001; 357 : 608–9. [Google Scholar]
  23. Berr C, Lambert JC, Sazdovitch V, et al. Neuropathological epidemiology of cerebral aging: a study of two genetic polymorphisms. Neurobiol Aging 2001; 22 : 227–35. [Google Scholar]
  24. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 1997; 42 : 776–82. [Google Scholar]
  25. Wolozin B. A fluid connection: cholesterol and Abeta. Proc Natl Acad Sci USA 2001; 98 : 5371–3. [Google Scholar]
  26. Mori T, Paris D, Town T, et al. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J Neuropathol Exp Neurol 2001; 60 : 778–85. [Google Scholar]
  27. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 2001; 8 : 890–9. [Google Scholar]
  28. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins ε3 and ε4 on neuronal growth in vitro. Science 1994; 264 : 850–2. [Google Scholar]
  29. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci 1994; 17 : 525–30. [Google Scholar]
  30. Egensperger R, Kosel S, von Eitzen U, Graeber MB. Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol 1998; 8 : 439–447. [Google Scholar]
  31. Lomnitski L, Chapman S, Hochman A, et al. Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury. Biochim Biophys Acta 1999; 1453 : 359–68. [Google Scholar]
  32. Barger SW, Mattson MP. Isoform-specific modulation by apolipoprotein E of the activities of secreted beta-amyloid precursor protein.J Neurochem 1997; 69 : 60–7. [Google Scholar]
  33. Miyata M, Smith JD.Apolipoprotein E allelespecific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14 : 55–61. [Google Scholar]
  34. Strittmatter WJ, Saunders AM, Goedert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 1994; 91 : 11183–6. [Google Scholar]
  35. Crutcher KA, Clay MA, Scott SA, Tian X, Tolar M, Harmony JA. Neurite degeneration elicited by apolipoprotein E peptides. Exp Neurol 1994; 130 : 120–6. [Google Scholar]
  36. Pericak-Vance MA, Bass MP, Yamaoka LH, et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 1997; 278 : 1237–41. [Google Scholar]
  37. Rogaeva E, Premkumar S, Song Y, et al. Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA 1998; 280 : 614–8. [Google Scholar]
  38. Kehoe P, Wavrant-DeVrieze F, Crook R, et al. A full genome scan for late onset Alzheimer’s disease. Hum Mol Genet 1999; 8 : 237–45. [Google Scholar]
  39. Wu WS, Holmans P, Wavrant-DeVrieze F, et al. Genetic studies on chromosome 12 in late-onset Alzheimer disease. JAMA 1998; 280 : 619–22. [Google Scholar]
  40. Scott WK, Grubber JM, Conneally PM, et al. Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. Am J Hum Genet 2000; 66 : 922–32. [Google Scholar]
  41. Lambert JC, Goumidi L, Vrieze FW, et al. The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic determinant of Alzheimer’s disease. Hum Mol Genet 2000; 9 : 2275–80. [Google Scholar]
  42. Hu Q, Kukull WA, Bressler SL, et al. The human FE65 gene: genomic structure and an intronic biallelic polymorphism associated with sporadic dementia of the Alzheimer type. Hum Genet 1998; 103 : 295–303. [Google Scholar]
  43. Cao X, Sudhof TC. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001; 293 : 115–20. [Google Scholar]
  44. Koster MN, Dermaut B, Cruts M, et al. The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology 2000; 55 : 678–84. [Google Scholar]
  45. Kang DE, Pietrzik CU, Baum L, et al. Modulation of amyloid beta-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000; 106 : 1159–66. [Google Scholar]
  46. Majores M, Bagli M, Papassotiropoulos A, et al. Allelic association between the D10S1423 marker and Alzheimer’s disease in a German population. Neurosci Lett 2000; 289 : 224–6. [Google Scholar]
  47. Zubenko GS, Hughes HB, Stiffler JS, Hurtt MR, Kaplan BB. A genome survey for novel Alzheimer disease risk loci: results at 10-cM resolution. Genomics 1998; 50 : 121–8. [Google Scholar]
  48. Ertekin-Taner N, Graff-Radford N, Younkin LH, et al. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer’s disease pedigrees. Science 2000; 290 : 2303–4. [Google Scholar]
  49. Pericak-Vance MA, Grubber J, Bailey LR, et al. Identification of novel genes in late-onset Alzheimer’s disease. Exp Gerontol 2000; 35 : 1343–52. [Google Scholar]
  50. Myers A, Holmans P, Marshall H, et al. Susceptibility locus for Alzheimer’s disease on chromosome 10. Science 2000; 290 : 2304–5. [Google Scholar]
  51. Bertram L, Blacker D, Mullin K, et al. Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q. Science 2000; 290 : 2302–3. [Google Scholar]
  52. Boussaha M, Campion D, Frebourg T. Les protéases impliquées dans la dégradation du peptide Aβ sont-elles des facteurs de risque pour la maladie d’Alzheimer ? Rev Neurol (Paris) 2001; 157 (suppl 10) : 4S10. [Google Scholar]
  53. Abraham R, Myers A, Wavrant-DeVrieze F, et al. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer’s disease. Hum Genet 2001; 109 : 646–52. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.